Smoking Cessation Study In Healthy Adolescent Smokers

Back to Search
Print
Bookmark Trial

NCT01312909

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
IICR, Inc. (DBA: International Institute of Clinical Research)
Ozark, Alabama, 36360, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Smoking Cessation
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
12-19 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Healthy male and female subjects between the ages of 12 and 19, inclusive.

- Subjects smoking at least an average of 5 cigarettes per day, motivated to stop smoking,

- Subjects must have at least one prior failed attempt to quit smoking.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Subjects with history, current diagnosis, or treatment of major depression disorder,
anxiety disorders, panic disorder, hostility or aggression disorder,
perceptual/thinking disturbances, mania, psychosis, bipolar disorder, personality
disorder, eating disorder or severe emotional problems (in the past year).


- Subjects with a prior suicide attempt: subjects hospitalized within the past 12 months
due to suicidal ideation or suicidal behavior; subjects considered to have serious
suicidal ideation or suicidal behavior in the past 12 months; active suicidal ideation
or behavior identified at the screening or baseline visit.


- Evidence of alcohol and substance abuse/dependence (other than nicotine) within 3
months prior to screening.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Smoking CessationEffectiveness of Combination Varenicline and Oral Nicotine Replacement Therapy (COMBO)
NCT03722966
  1. Oklahoma City, Oklahoma
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Smoking CessationMessage Priming and Enrollment in, and Response to, a Smoking Cessation Program: A Pilot Study
NCT00596882
  1. Philadelphia, Pennsylvania
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Smoking CessationAn Alternative Dosing Schedule of Varenicline for Smoking Cessation
NCT00835900
  1. Buffalo, New York
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Smoking CessationVarenicline In-Patient Study
NCT01413516
  1. Stanford, California
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Smoking Cessation Study In Healthy Adolescent Smokers
Official Title  ICMJE A Twelve-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study With Follow-up Evaluating The Safety And Efficacy Of Varenicline For Smoking Cessation In Healthy Adolescent Smokers
Brief Summary The study is designed to see if varenicline combined with age appropriate (adolescent) smoking cessation counseling will help teens quit smoking.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Smoking Cessation
Intervention  ICMJE
  • Drug: Varenicline 1mg BID
    Oral Varenicline 1mg BID, or 1/2 that dose (0.5mg BID) for those subjects that weigh less than or equal to 55kg at baseline, for twelve weeks, follow-up through Week 52
  • Drug: Varenicline 0.5mg BID
    Oral Varenicline 0.5mg BID, or 1/2 that dose (0.5 QD) for those subjects that weigh less than or equal to 55kg at baseline, for twelve weeks, follow-up through Week 52
  • Drug: Placebo
    Oral placebo for twelve weeks,follow-up through Week 52
Study Arms  ICMJE
  • Experimental: Varenicline 1mg BID
    Oral Varenicline 1mg BID, or 1/2 that dose (0.5mg BID) for those subjects that weigh less than or equal to 55kg at baseline, for twelve weeks, follow-up through Week 52
    Intervention: Drug: Varenicline 1mg BID
  • Experimental: Varenicline 0.5mg BID
    Oral Varenicline 0.5mg BID, or 1/2 that dose (0.5 QD) for those subjects that weigh less than or equal to 55kg at baseline, for twelve weeks, follow-up through Week 52
    Intervention: Drug: Varenicline 0.5mg BID
  • Placebo Comparator: Placebo
    Oral placebo for twelve weeks,follow-up through Week 52
    Intervention: Drug: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: May 29, 2018)		312
Original Estimated Enrollment  ICMJE
 (submitted: March 9, 2011)		300
Actual Study Completion Date  ICMJE January 2018
Actual Primary Completion Date January 2018   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Healthy male and female subjects between the ages of 12 and 19, inclusive.
  • Subjects smoking at least an average of 5 cigarettes per day, motivated to stop smoking,
  • Subjects must have at least one prior failed attempt to quit smoking.

Exclusion Criteria:

  • Subjects with history, current diagnosis, or treatment of major depression disorder, anxiety disorders, panic disorder, hostility or aggression disorder, perceptual/thinking disturbances, mania, psychosis, bipolar disorder, personality disorder, eating disorder or severe emotional problems (in the past year).
  • Subjects with a prior suicide attempt: subjects hospitalized within the past 12 months due to suicidal ideation or suicidal behavior; subjects considered to have serious suicidal ideation or suicidal behavior in the past 12 months; active suicidal ideation or behavior identified at the screening or baseline visit.
  • Evidence of alcohol and substance abuse/dependence (other than nicotine) within 3 months prior to screening.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 12 Years to 19 Years   (Child, Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada,   Georgia,   Korea, Republic of,   Russian Federation,   Taiwan,   United States
Removed Location Countries Israel
 
Administrative Information
NCT Number  ICMJE NCT01312909
Other Study ID Numbers  ICMJE A3051073
CHANTIX ( Other Identifier: Alias Study Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date July 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP